DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inflammatory Bowel Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Inflammatory Bowel Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Recent Breakthroughs in the Inflammatory Bowel Disease Market:
In September 2023, Cosmo Pharmaceuticals and Adalvo have entered into a license and supply agreement for Rifamycin SV with MMX technology across Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA), and Latin America (LATAM) regions.
In May 2023, NGM Biopharmaceuticals announced that findings from a Phase II investigator-sponsored trial of aldafermin for treating patients with idiopathic bile acid malabsorption (BAM) alongside irritable bowel syndrome with diarrhea (IBS-D) were presented at Digestive Disease Week 2023.
Inflammatory Bowel Disease Overview
Inflammatory Bowel Disease (IBD) refers to a group of disorders that cause chronic inflammation of the gastrointestinal (GI) tract. The two main types of IBD are Crohn’s disease and ulcerative colitis.
Crohn’s Disease
Location: Can affect any part of the GI tract from the mouth to the anus, but most commonly affects the end of the small intestine (ileum) and the beginning of the colon.
Characteristics: Inflammation can occur in patches and can penetrate through multiple layers of the bowel walls.
Symptoms: Abdominal pain, diarrhea (sometimes with blood), weight loss, and fatigue.
Ulcerative Colitis
Location: Limited to the colon (large intestine) and rectum.
Characteristics: Inflammation is continuous and affects only the innermost lining of the colon.
Symptoms: Bloody diarrhea, abdominal pain, urgency to defecate, and weight loss.
Common Symptoms of IBD
Persistent diarrhea
Abdominal pain and cramping
Rectal bleeding
Fatigue and loss of energy
Weight loss
Reduced appetite
Causes and Risk Factors
The exact cause of IBD is unknown, but it is believed to result from a combination of factors:
Genetics: A family history of IBD increases the risk.
Immune System: An abnormal immune response can trigger inflammation in the GI tract.
Environmental Factors: Diet, smoking, and use of nonsteroidal anti-inflammatory drugs (NSAIDs) may contribute.
Diagnosis
Blood Tests: To check for anemia or infection.
Stool Tests: To rule out infections and detect inflammation.
Endoscopic Procedures: Colonoscopy and sigmoidoscopy to visualize the GI tract and take biopsies.
Imaging Studies: CT scan, MRI, or X-rays to examine the GI tract.
Inflammatory Bowel Disease Market Key Facts
In 2023, the United States had the largest number of cases among the 7MM, with approximately 14 million prevalent cases. These numbers are anticipated to rise in the forecast period.
In the United States in 2023, irritable bowel syndrome was more prevalent among females than males in terms of total gender-specific cases.
In 2023, Germany had the highest prevalence of irritable bowel syndrome among the EU4 and the UK, whereas Spain reported the lowest number of cases.
Inflammatory Bowel Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Inflammatory Bowel Disease Epidemiology, Segmented as –
Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM
Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM
Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) (e.g., Ulcerative colitis, Crohn’s Disease, and Unspecified) in the 7MM
Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM
Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the 7MM
Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities
Learn How the Inflammatory Bowel Disease Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market
Inflammatory Bowel Disease Therapeutics Analysis
Blautix: CJ Bioscience/4D Pharma
BEKINDA (RHB-102): RedHill Biopharma
TRP-8802: Tryp Therapeutics
Mirikizumab: Eli Lilly and Company
Filgotinib: Gilead/ Galapagos
AMT-101: Applied Molecular Transport
PN-943: Protagonist Therapeutics
Tremfya: Janssen
Brazikumab: AstraZeneca
Leading Companies in the Inflammatory Bowel Disease Therapeutics Market Include:
Takeda
AstraZeneca
Janssen Pharmaceuticals
Abbvie
Eli Lilly and Company
Applied Molecular Transport
Janssen
Gilead
Galapagos
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Inflammatory Bowel Disease Competitive Intelligence Analysis
4. Inflammatory Bowel Disease Market Overview at a Glance
5. Inflammatory Bowel Disease Disease Background and Overview
6. Inflammatory Bowel Disease Patient Journey
7. Inflammatory Bowel Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Inflammatory Bowel Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Inflammatory Bowel Disease Unmet Needs
10. Key Endpoints of Inflammatory Bowel Disease Treatment
11. Inflammatory Bowel Disease Marketed Products
12. Inflammatory Bowel Disease Emerging Drugs and Latest Therapeutic Advances
13. Inflammatory Bowel Disease Seven Major Market Analysis
14. Attribute Analysis
15. Inflammatory Bowel Disease Market Outlook (In US, EU5, and Japan)
16. Inflammatory Bowel Disease Access and Reimbursement Overview
17. KOL Views on the Inflammatory Bowel Disease Market
18. Inflammatory Bowel Disease Market Drivers
19. Inflammatory Bowel Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
